Related Experiment Videos
Interest in Extended Release Naltrexone among Opioid Users
Kamni Sharma Haase1, Nikolaj Kunøe, Arild Opheim
1Norwegian Centre for Addiction Research (SERAF), Oslo, Norway.
European Addiction Research
|July 20, 2016
Summary
Opioid users show significant interest in extended-release naltrexone injections for addiction treatment. This finding suggests that patient willingness is not a barrier to implementing this opioid-blocking medication.
Area of Science:
- Addiction medicine
- Pharmacology
- Public health
Background:
- Current opioid addiction treatments include medically assisted maintenance and medication-free abstinence.
- Naltrexone, an opioid antagonist, is rarely used for assisted abstinence, possibly due to user reluctance or perceived limited efficacy.
- Extended-release naltrexone injections offer a 4-5 week blockade of illicit opioids, supporting abstinence.
Purpose of the Study:
- To assess opioid users' interest in a 4-weekly extended-release naltrexone injection for addiction treatment.
- To determine if user interest is a significant factor hindering the adoption of this treatment modality.
Main Methods:
- A questionnaire was administered to opioid users across various outreach facilities.
- A total of 731 surveys were analyzed to gauge treatment preferences.
Main Results:
- Over half of the participants (n=421) expressed strong interest in a year-long, 4-weekly opioid-blocking medication.
- Less than a quarter (n=164) reported no interest in the treatment.
Conclusions:
- There is substantial interest among opioid users for naltrexone treatment.
- User interest does not appear to be a barrier to the implementation of extended-release naltrexone injections.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.3K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.3K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
162
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
162
01:22Opioid Receptors: Overview
6.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.0K
01:19Modified-Release Drug Delivery Systems: Overview
99
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
99
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
131
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
131
01:25Analgesia and Pain Management
2.7K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.7K